{{Drugbox
| Watchedfields = changed
| verifiedrevid = 437877399
| IUPAC_name = (''RS'')-3-[2-(ethylamino)-1-hydroxyethyl]phenol
| image = Etilefrine.svg
| width = 200px
| chirality = [[Racemic mixture]]

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|etilefrine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 709-55-7
| ATC_prefix = C01
| ATC_suffix = CA01
| PubChem = 3306
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08985 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3190
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ZB6F8MY53V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07931
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 86882

<!--Chemical data-->
| C=10 | H=15 | N=1 | O=2 
| molecular_weight = 181.232 g/mol
| smiles = OC(CNCC)c1cc(O)ccc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SQVIAVUSQAWMKL-UHFFFAOYSA-N
| synonyms = (2-ethylamino-1-(3'-hydroxy-phenyl)ethanol
}}

'''Etilefrine''' is a [[cardiac stimulant]] used as an [[Antihypotensive agent|antihypotensive]]. It is a [[sympathomimetic amine]] of the 3-hydroxy-phenylethanolamine series used in treating [[orthostatic hypotension]] of neurological, cardiovascular, endocrine or metabolic origin. [[Intravenous infusion]] of this compound increases [[cardiac output]], [[stroke volume]], [[Venous return curve|venous return]] and blood pressure in man and experimental animals, suggesting stimulation of both α and [[Β-adrenergic receptors|β adrenergic receptors]].<ref>Nusser, Donath and Russ, 1965; Mellander,
1966; Limbourg, Just and Lang, 1973; Tarnow et al.~1973; Carrera and Aguilera, 1973.</ref> However, ''[[in vitro]]'' studies indicate that etilefrine has a much higher affinity for β<sub>1</sub> (cardiac) than for β<sub>2</sub> [[adrenoreceptors]].<ref>Offermeier and Dreyer, 1971.</ref>

Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, [[central venous pressure]] and [[mean arterial pressure]] of healthy individuals. [[Peripheral vascular resistance]] falls during the infusion of 1–8&nbsp;mg etilefrine but begins to rise at higher dosage. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous [[propranolol]] 2,5&nbsp;mg. These findings indicate that etilefrine has both β<sub>1</sub> and [[Alpha-1 adrenergic receptor|α<sub>1</sub> adrenergic]] effects in man.

== References ==
{{Reflist}}

== External links ==
* [https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3306 PubChem: Etilefrine]
* [http://www.genome.jp/dbget-bin/www_bget?dr:D07931 Kegg:  Etilefrine]

{{Cardiac stimulants excluding cardiac glycosides}}
{{Adrenergics}}
{{Phenethylamines}}

[[Category:Alcohols]]
[[Category:Beta1-adrenergic agonists]]
[[Category:Cardiac stimulants]]
[[Category:Phenethylamines]]
[[Category:Phenols]]